Assessment of the efficacy and safety of fampridine
<p><strong>Objective:</strong> Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis.</p> <p><strong>Method:</strong> A descriptive retrospective study of all patients who initiated treatment w...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/10615.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037855662899200 |
|---|---|
| author | Beatriz Mejuto Paloma Castellano Concepción Castro Luis Manuel López |
| author_facet | Beatriz Mejuto Paloma Castellano Concepción Castro Luis Manuel López |
| author_sort | Beatriz Mejuto |
| collection | DOAJ |
| description | <p><strong>Objective:</strong> Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis.</p>
<p><strong>Method:</strong> A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial.</p>
<p><strong>Results:</strong> Six patients were included, with a 66.7% response rate. At 3-6 months, the mean change in walking speed (compared to baseline) was 39.32% and there was a mean improvement of 15 points in the walking scale. Only one patient presented adverse effects.</p>
<p><strong>Conclusions:</strong> The results obtained are encouraging, particularly when fampridine is the only drug currently approved to control such a disabling symptom as instability while walking. </p> |
| format | Article |
| id | doaj-art-e41c9db980cf424892e569879a23921f |
| institution | DOAJ |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2017-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-e41c9db980cf424892e569879a23921f2025-08-20T02:56:45ZengElsevierFarmacia Hospitalaria1130-63432171-86952017-03-0141228329110.7399/fh.2017.41.2.10615Assessment of the efficacy and safety of fampridineBeatriz Mejuto0Paloma Castellano1Concepción Castro2Luis Manuel López3Pharmacy Unit. Hospital da Costa. EOXI Lugo, Monforte e Cervo.Pharmacy Unit. Hospital da Costa. EOXI Lugo, Monforte e Cervo.Pharmacy Unit. Hospital da Costa. EOXI Lugo, Monforte e CervoPharmacy Unit. Hospital da Costa. EOXI Lugo, Monforte e Cervo<p><strong>Objective:</strong> Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis.</p> <p><strong>Method:</strong> A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial.</p> <p><strong>Results:</strong> Six patients were included, with a 66.7% response rate. At 3-6 months, the mean change in walking speed (compared to baseline) was 39.32% and there was a mean improvement of 15 points in the walking scale. Only one patient presented adverse effects.</p> <p><strong>Conclusions:</strong> The results obtained are encouraging, particularly when fampridine is the only drug currently approved to control such a disabling symptom as instability while walking. </p>http://www.aulamedica.es/fh/pdf/10615.pdfFampridine; Multiple sclerosis; Efficacy; Safety |
| spellingShingle | Beatriz Mejuto Paloma Castellano Concepción Castro Luis Manuel López Assessment of the efficacy and safety of fampridine Farmacia Hospitalaria Fampridine ; Multiple sclerosis ; Efficacy ; Safety |
| title | Assessment of the efficacy and safety of fampridine |
| title_full | Assessment of the efficacy and safety of fampridine |
| title_fullStr | Assessment of the efficacy and safety of fampridine |
| title_full_unstemmed | Assessment of the efficacy and safety of fampridine |
| title_short | Assessment of the efficacy and safety of fampridine |
| title_sort | assessment of the efficacy and safety of fampridine |
| topic | Fampridine ; Multiple sclerosis ; Efficacy ; Safety |
| url | http://www.aulamedica.es/fh/pdf/10615.pdf |
| work_keys_str_mv | AT beatrizmejuto assessmentoftheefficacyandsafetyoffampridine AT palomacastellano assessmentoftheefficacyandsafetyoffampridine AT concepcioncastro assessmentoftheefficacyandsafetyoffampridine AT luismanuellopez assessmentoftheefficacyandsafetyoffampridine |